
A groundbreaking study utilized artificial intelligence (AI) to forecast treatment needs, visual acuity, and morphological results in neovascular age-related macular degeneration (nAMD). They processed optical coherence tomography data from 158 treatment-naïve nAMD patients, using AI to quantify intraretinal and subretinal fluid and pigment epithelial detachment volumes. The study's predictive model achieved an accuracy of 0.77 in predicting injection requirements for the first year and showed the importance of baseline visual acuity in forecasting final outcomes. The AI model could differentiate between macular atrophy and non-MA eyes with an accuracy of 0.70 over four years, and it achieved an accuracy of 0.74 in predicting subretinal fibrosis.
Like
Save
Share